This grant proposal is a competitive renewal of a project we have pursued for 10 years directed at understanding the mechanism of action of the vitamin D receptor (VDR) as the mediator of 1,25-dihydroxyvitamin D (1,25D) action. The project has supported the publication of many original research papers as well as reviews of the field, editorials, chapters and the editing of two multi-authored books. The next support period will continue our investigation into the role of the VDR in clinically relevant situations in which 1,25D activity is enhanced or suppressed by either genetic factors (mutations or polymorphisms) or physiologic factors (regulators of VDR abundance or action). The clinical diseases most relevant to the project are:
Aim I, rickets;
Aim II, osteoporosis;
and Aim III, prostate cancer.
Specific Aim I will investigate Hereditary Vitamin D Resistant Rickets (HVDRR) and elucidate loss of function mutations causing rickets and a gain of function mutation causing hypercalcemia. An additional project will study the use of 1,25D analogs to activate mutant VDRs and treat HVDRR patients.
Specific Aim II will focus on the structure of the VDR and will examine factors that regulate the abundance of receptors and the capacity of the VDR to mediate 1,25D actions. Sub-Aim 1 will investigate the VDR promoter. Sub-Aim 2 will investigate the VDR promoter variants leading to N-terminal isoforms and evaluate their differential functional potency and tissue distribution. Sub-Aim 3 will investigate VDR polymorphisms and the ability of the variant receptors to respond to 1,25D and analogs with target gene activation.
Specific Aim III will focus on 1,25D actions. The sub-Aims will involve cDNA microarray analysis to identify new target genes in prostate cancer and bone; a further analysis of IGFBP-3 as a target gene that mediates some of the anti-prostate cancer activity of 1,25D; and an analysis of the negative vitamin D response element (nVDRE) in new target genes including the estrogen receptor and IGFBP-3. Many of the projects will be carried out in collaboration with leading researchers in their respective fields. Comprehensive preliminary data and an extensive track record support our ability to successfully conduct this large, multi-phasic study. The long-term goals of the grant proposal are to provide further insight into the mechanism of 1,25D action and to understand the role of the VDR in affecting disease risk, pathogenesis and treatment of rickets, osteoporosis and prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK042482-13
Application #
6771048
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Malozowski, Saul N
Project Start
1991-06-01
Project End
2005-09-19
Budget Start
2004-07-01
Budget End
2005-09-19
Support Year
13
Fiscal Year
2004
Total Cost
$337,387
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Malloy, Peter J; Tasic, Velibor; Taha, Doris et al. (2014) Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets. Mol Genet Metab 111:33-40
Huang, Karen; Malloy, Peter; Feldman, David et al. (2013) Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation. Gene 512:554-9
Sequeira, Vanessa B; Rybchyn, Mark S; Tongkao-On, Wannit et al. (2012) The role of the vitamin D receptor and ERp57 in photoprotection by 1?,25-dihydroxyvitamin D3. Mol Endocrinol 26:574-82
Malloy, Peter J; Zhou, Yulin; Wang, Jining et al. (2011) Hereditary vitamin D-resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor. J Bone Miner Res 26:2710-8
Malloy, Peter J; Feldman, David (2011) The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol 347:90-6
Aljubeh, Jamal M; Wang, Jining; Al-Remeithi, Sareea S et al. (2011) Report of two unrelated patients with hereditary vitamin D resistant rickets due to the same novel mutation in the vitamin D receptor. J Pediatr Endocrinol Metab 24:793-9
Krishnan, Aruna V; Feldman, David (2010) Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 17:R19-38
Malloy, Peter J; Feldman, David (2010) Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am 39:333-46, table of contents
Forghani, Nikta; Lum, Catherine; Krishnan, Sowmya et al. (2010) Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene. J Pediatr Endocrinol Metab 23:843-50
Malloy, Peter J; Wang, Jining; Srivastava, Tarak et al. (2010) Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Mol Genet Metab 99:72-9

Showing the most recent 10 out of 20 publications